Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial

American Heart Journal
Shaul AtarYochai Birnbaum

Abstract

It has recently been shown that statins increase the myocardial content of prostaglandin (PG) I2 (prostacyclin) and PGE2. A systemic increase of PG production may protect the gastric mucosa and prevent gastrointestinal (GI) bleeding. We hypothesized that statins would lower the risk of GI bleeding associated with antiplatelet therapy in patients with acute coronary syndromes (ACS). We retrospectively analyzed data on 10288 patients with ACS included in the OPUS-TIMI 16 trial and received aspirin and either the oral IIb/IIIa inhibitor orbofiban or placebo. Inhospital GI bleeding rate was significantly lower in patients who were receiving lipid-lowering drugs before admission compared with those who were not (0.2% vs 0.6%, P = .031). Throughout 10 months of follow-up, GI bleeding occurred in 1.8% of non-statin users compared with 1.0% of statin users (P = .001). Statin use was associated with less overall bleeding in both the orbofiban (1.4% vs 2.4%, P = .006) and the placebo groups (0.2% vs 0.8%, P = .047). Severe and major bleeding occurred less frequently with statin use (0.8% vs 1.5%, P = .001) in both the orbofiban (1.1% vs 2.0%, P = .006) and the placebo groups (0.1% vs 0.5%, P = .119). Logistic regression analysis showed t...Continue Reading

References

Dec 28, 1999·JAMA : the Journal of the American Medical Association·J C LaRosaS Vupputuri
Jun 17, 2004·Circulation·Jean Davignon
Dec 1, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Anetta UndasKenneth G Mann
Jan 11, 2005·Cardiovascular Research·Cherry L Wainwright
Jan 11, 2005·Cardiovascular Research·Yochai BirnbaumBarry F Uretsky

❮ Previous
Next ❯

Citations

Dec 29, 2000·Journal of the American College of Cardiology·D P Chew, D J Moliterno
Jan 23, 2009·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Beatrice A Golomb, Marcella A Evans
May 15, 2013·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Kamil KarolczakCezary Watala
Jun 23, 2015·Pharmacoepidemiology and Drug Safety·Ricardo BadilloIshak Mansi
Apr 18, 2009·British Journal of Clinical Pharmacology·Sinem Ezgi GulmezJesper Hallas
Jun 25, 2015·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Kazumasa MiyakeChoitsu Sakamoto
Sep 25, 2016·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Faraz Khan LuniSadik A Khuder
Jul 9, 2008·Journal of Clinical Gastroenterology·Kassem BaradaPeter H Green
Sep 28, 2007·Drugs & Aging·Angelo ZulloSergio Morini
Nov 26, 2009·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Abhimanyu BeriSnigdha B Mahajan
Nov 23, 2011·Pharmacological Reviews·Patrizia GazzerroMaurizio Bifulco
May 5, 2018·Journal of Clinical Medicine·Nijole BernaitisShailendra Anoopkumar-Dukie
Dec 19, 2018·Medicine·Monica PanteaSimona Băţagă
Dec 15, 2006·Journal of Thrombosis and Haemostasis : JTH·R R HantganS A Mousa
Sep 27, 2018·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Ashley I MartinezDaniela C Moga
Feb 11, 2021·BioMed Research International·Antonio NennaMassimo Chello

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.